ReviewProceedings of the Japan Academy. Series B, Physical and biological sciences2010
Transthyretin-related familial amyloidotic polyneuropathy-Progress in Kumamoto, Japan (1967-2010)-.
Review in Proceedings of the Japan Academy. Series B, Physical and biological sciences, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Hereditary Transthyretin Amyloidosis (hATTR) with Polyneuropathy Clusters Are Located in Ancient Mining Districts: A Possible Geochemical Origin of the Disease.Biomolecules · 2024Review
- Urinary Transthyretin as a Biomarker in ATTRv Val50Met Amyloidosis.Pathophysiology : the official journal of the International Society for Pathophysiology · 2022Article
- Proteins in Wonderland: The Magical World of Pressure.Biology · 2021Article
- Increased Risk of Multiple Outpatient Surgeries in African-American Carriers ofJournal of clinical medicine · 2019Article
- Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series.Orphanet journal of rare diseases · 2019Review
- Amyloidosis due to TTR mutations in Mexico with 4 distincts genotypes in the index cases.Orphanet journal of rare diseases · 2018Article
- Novel Antibody for the Treatment of Transthyretin Amyloidosis.The Journal of biological chemistry · 2016Article
- Article
- Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France.Annals of neurology · 2015Article
- Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis.Molecules (Basel, Switzerland) · 2015Review
- FAP neuropathy and emerging treatments.Current neurology and neuroscience reports · 2014Review
- Mutation p.G83R in the transthyretin gene is associated with hereditary vitreous amyloidosis in Han Chinese families.Molecular vision · 2013Article
- Amyloid neuropathies.The Mount Sinai journal of medicine, New YorkReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The authors reviewed contribution of Kumamoto University group to the progress of the studies on transthyretin (TTR)-related familial amyloidotic polyneuropathy (TTR-related FAP) for 42 years (from 1967 to 2009). Andrade (1952) first described a large group of patients with FAP in Portugal and Araki et al. (1967) in second discovered similar FAP patients in Arao, Kumamoto, Japan. Owing to progress in biochemical and molecular genetic analyses, FAP is now believed to occur worldwide. As of today, reports of about 100 different points of single or two mutations, or a deletion in the transthyretin (TTR) gene, have been published. The authors' group has made pioneer works for study of FAP in the world. The focus on therapy in amylodosis will increase sharply as an impetus in near future, and successful treatments are expected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.